The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM Vaccine
Abstract
BACKGROUND: The immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) was assessed and compared with the 7-valent pneumococcal conjugate vaccine (7vCRM). METHODS: Healthy subjects (1650) were randomized to be vaccinated with 3 doses of PHiD-CV or 7vCRM (Prevenar/Prevnar) at 2-3-4 months of age and a fourth booster dose at 12-18 months. Serotype-specific pneumococcal responses (GlaxoSmithKline's ELISA with 22F-inhibition) and opsonophagocytic activity (OPA) were measured 1 month after primary and booster vaccinations. RESULTS: The primary objective to demonstrate noninferiority of PHiD-CV versus 7vCRM (in terms of percentage of subjects with antibody concentration >or=0.2 microg/mL) for at least 7 of the 10 vaccine serotypes was reached as noninferiority was demonstrated for 8 serotypes. Although, noninferiority could not be demonstrated for ELISA responses against serotypes 6B and 23F, a post-hoc analysis of the percentage of subjects with OPA titers >or=8 suggested noninferiority for the 7 serotypes common to both vaccines including 6B and 23F.Priming of the immune system against all vaccine serotypes was confirmed by robust increases in ELISA antibody levels ( approximately 6.0-17 fold) and OPA titers ( approximately 8-93 fold) after a fourth consecutive dose of PHiD-CV. CONCLUSIONS: PHiD-CV induces ELISA and functional OPA antibodies for all vaccine serotypes after primary vaccination and is noninferior to 7vCRM in terms of ELISA and/or OPA threshold responses. Effective priming is further indicated by robust booster responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
BLACK, S., SHINEFIELD, H., FIREMAN, B., LEWIS, E., RAY, P., HANSEN, J. R., ELVIN, L., ENSOR, K. M., HACKELL, J., SIBER, G., et al. (2000) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200003000-00003 · Cited by 2,293
Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis Media
Eskola, J., Kilpi, T., Palmu, A., Jokinen, J., Eerola, M., Haapakoski, J., Herva, E., Takala, A., Käyhty, H., Karma, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102083440602 · Cited by 1,455
Klugman, K. P., Madhi, S. A., Huebner, R. E., Kohberger, R., Mbelle, N., & Pierce, N. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035060 · Cited by 1,009
Prymula, R., Peeters, P., Chrobok, V., Kriz, P., Novakova, E., Kaliskova, E., Kohl, I., Lommel, P., Poolman, J., Prieels, J.-P., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68304-9 · Cited by 637
Self-citationPrymula, R., Peeters, P., Chrobok, V., Kriz, P., Novakova, E., Kaliskova, E., Kohl, I., Lommel, P., Poolman, J., Prieels, J., et al. (2006) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2006.01314.x · Cited by 522
Self-citationPopulation Snapshot of Emergent Streptococcus pneumoniae Serotype 19A in the United States, 2005
Moore, M. R., Gertz, Jr., Woodbury, R. L., Barkocy‐Gallagher, G. A., Schaffner, W., Lexau, C., Gershman, K., Reingold, A., Farley, M., Harrison, L. H., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/528996 · Cited by 480
Dynamics of nasopharyngeal colonization by potential respiratory pathogens
García-Rodríguez, J. Á., & Fresnadillo Martínez, M. J. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf506 · Cited by 404
Jódar, L., Butler, J., Carlone, G., Dagan, R., Goldblatt, D., Käyhty, H., Klugman, K., Plikaytis, B., Siber, G., Kohberger, R., et al. (2003) · Vaccine · doi:10.1016/s0264-410x(03)00230-5 · Cited by 388
O'Brien, K. L., Moulton, L. H., Reid, R., Weatherholtz, R., Oski, J., Brown, L., Kumar, G., Parkinson, A., Hu, D., Hackell, J., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14022-6 · Cited by 388
Pathogenesis of Pneumococcal Infection
Tuomanen, E. I., Austrian, R., & Masure, H. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505113321907 · Cited by 381
Cited by
Burden of Community-Acquired Pneumonia in North American Adults
File, T. M., & Marrie, T. J. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.03.2130 · Cited by 472
Prymula, R., Siegrist, C.-A., Chlibek, R., Zemlickova, H., Vackova, M., Smetana, J., Lommel, P., Kaliskova, E., Borys, D., & Schuerman, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61208-3 · Cited by 372
Self-citationGlycoconjugate vaccines and immune interference: A review
Dagan, R., Poolman, J., & Siegrist, C.-A. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.06.026 · Cited by 270
Protein carriers of conjugate vaccines: Characteristics, development and clinical trials
Pichichero, M. E. (2013) · Human vaccines & immunotherapeutics · doi:10.4161/hv.26109 · Cited by 261
Voysey, M., Kelly, D. F., Fanshawe, T. R., Sadarangani, M., O’Brien, K. L., Perera, R., & Pollard, A. J. (2017) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2017.0638 · Cited by 141
Metadata
- Authors
- Vesikari, T., Wysocki, J., Chevallier, B., Karvonen, A., Czajka, H., Arsène, J.-P., Lommel, P., Dieussaert, I., & Schuerman, L.
- Venue
- Pediatric Infectious Disease Journal
- Published
- 2009-04
- Volume
- 28
- Issue
- 4
- Pages
- S66-S76
- ISSN
- 0891-3668 (ISSN-L)
- OpenAlex
- W2092915795
- Cited by
- 268
- References
- 36
- FWCI
- 22.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM Vaccine. https://app.cochat.ai/papers/10.1097/inf.0b013e318199f8ef
- The paper
- Vesikari, T., Wysocki, J., Chevallier, B., Karvonen, A., Czajka, H., Arsène, J.-P., Lommel, P., Dieussaert, I., & Schuerman, L. (2009). Immunogenicity of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the Licensed 7vCRM Vaccine. Pediatric Infectious Disease Journal. https://doi.org/10.1097/inf.0b013e318199f8ef
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.